eShowcase: EDC 2.0
New Version of EDC Solution Builds on Web Capabilities for Integration and Study Deployment
New Version of EDC Solution Builds on Web Capabilities for Integration and Study Deployment
etrials Worldwide (Morrisville, NC) has released EDC 2.0, the latest version of its software for pharmaceutical companies used to collect, manage, and analyze clinical trial information.
EDC 2.0 is Web-based and can integrate with etrials eDiary and IVR solutions to provide a more comprehensive e-clinical solution.
Also, because it is Web-based, it can be accessed by study sites and provides user-directed functions and design. The product also includes new reporting and configuration capabilities. Other functions include Electronic Case Report Forms (eCRF), workflow manager, a Message/Alert manager that uses a message center to connect and communicate with sites and investigators, a Reporting/Analytics function, and a Design Manager to improve application interfaces for increased user function.
Data is housed in a single data repository and includes the ability to integrate study-related data using Data Xchange.
etrials Worldwide, (919) 653-3400, www.etrials.com
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
